Ind-Swift Laboratories Ltd. (IN:INDSWFTLAB)
:INDSWFTLAB
INDSWFTLAB Stock Chart & Stats
₹90.70
-₹2.17(-1.99%)
At close: 4:00 PM EST
₹90.70
-₹2.17(-1.99%)
Day’s Range― - ―
52-Week Range₹67.15 - ₹151.95
Previous CloseN/A
Volume31.71K
Average Volume (3M)7.30K
Market Cap
₹11.34B
Enterprise Value₹7.49B
Total Cash (Recent Filing)₹4.33B
Total Debt (Recent Filing)₹220.47M
Price to Earnings (P/E)18.9
Beta1.29
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.17
Shares Outstanding81,611,560
10 Day Avg. Volume7,859
30 Day Avg. Volume7,299
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.46
Price to Sales (P/S)0.96
P/FCF Ratio-5.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained top-line expansion of ~25.6% indicates persistent demand and successful commercial traction across products or markets. Over 2–6 months this growth supports scalable operations, better bargaining power with suppliers, and a larger revenue base to absorb fixed costs, aiding durable margin recovery.
Very Low LeverageExtremely low debt levels provide financial flexibility and reduce bankruptcy risk. This allows management to fund capex or R&D from equity or operating cash, pursue M&A, and withstand industry cyclicality without material refinancing pressure, supporting long-term strategic options.
High Return On EquityA near-45% ROE shows the company converts equity into profits efficiently, implying strong profitability drivers or asset-light advantages. Persistently high ROE suggests competitive advantages, pricing power, or efficient capital allocation that can sustain shareholder returns over multiple quarters.
Bears Say
Negative Operating Cash FlowRepeated negative operating and free cash flows signal weak cash conversion of earnings and potential liquidity strain. Over several months this limits capacity to self-fund capex, dividends, or debt repayment, forcing reliance on equity or external financing and increasing execution risk.
Negative EBIT MarginA negative EBIT margin despite revenue growth points to structural cost or gross-margin pressure, such as rising COGS, pricing stress, or elevated operating expenses. If persistent, it undermines operating leverage and the sustainability of profits even as sales rise.
Declining EPS GrowthA decline in EPS growth indicates earnings per share are contracting, raising concerns about earnings quality and the durability of profitability. Over the medium term this may reflect margin compression, one-off items, or dilution risks that can constrain reinvestment and shareholder returns.
Ind-Swift Laboratories Ltd. News
INDSWFTLAB FAQ
What was Ind-Swift Laboratories Ltd.’s price range in the past 12 months?
Ind-Swift Laboratories Ltd. lowest stock price was ₹67.15 and its highest was ₹151.95 in the past 12 months.
What is Ind-Swift Laboratories Ltd.’s market cap?
Ind-Swift Laboratories Ltd.’s market cap is ₹11.34B.
When is Ind-Swift Laboratories Ltd.’s upcoming earnings report date?
Ind-Swift Laboratories Ltd.’s upcoming earnings report date is Jun 03, 2026 which is in 58 days.
How were Ind-Swift Laboratories Ltd.’s earnings last quarter?
Ind-Swift Laboratories Ltd. released its earnings results on Jan 31, 2026. The company reported ₹1.169 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.169.
Is Ind-Swift Laboratories Ltd. overvalued?
According to Wall Street analysts Ind-Swift Laboratories Ltd.’s price is currently Overvalued.
Does Ind-Swift Laboratories Ltd. pay dividends?
Ind-Swift Laboratories Ltd. pays a Annually dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Ind-Swift Laboratories Ltd. dividends here
What is Ind-Swift Laboratories Ltd.’s EPS estimate?
Ind-Swift Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ind-Swift Laboratories Ltd. have?
Ind-Swift Laboratories Ltd. has 81,611,560 shares outstanding.
What happened to Ind-Swift Laboratories Ltd.’s price movement after its last earnings report?
Ind-Swift Laboratories Ltd. reported an EPS of ₹1.169 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.07%.
Which hedge fund is a major shareholder of Ind-Swift Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:INDSWFTLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ind-Swift Laboratories Ltd.
Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.
Technical Analysis
Medicamen Biotech Limited
―
Nectar Lifesciences Ltd.
―
Sakar Healthcare Ltd
―
Venus Remedies Limited
―
Zim Laboratories Ltd.
―